TYK2

Assets acting on this target.

Class
TYK2 inhibitor

TYK2 (tyrosine kinase 2) is a member of the Janus kinase (JAK) family, a group of enzymes that sit just inside the cell membrane and relay signals from cytokine receptors to the nucleus. TYK2 specifically partners with receptors for interleukin-12 (IL-12), interleukin-23 (IL-23), and type I interferons (cytokines that drive many of the inflammatory and autoimmune processes seen in psoriasis, psoriatic arthritis, inflammatory bowel disease, and lupus). When these cytokines bind their receptors, TYK2 helps activate STAT transcription factors, which switch on genes that sustain inflammation. Blocking TYK2 dampens this signaling cascade, reducing the downstream inflammatory output without shutting down cytokine signaling entirely elsewhere in the body. What distinguishes many newer TYK2 inhibitors is that they bind a regulatory region of the enzyme called the pseudokinase (JH2) domain rather than its catalytic site, allowing selective inhibition of TYK2 while sparing closely related JAK1, JAK2, and JAK3, which govern blood cell production, growth factor signaling, and broader immune function. This selectivity is the biological rationale for developing TYK2-specific agents: it aims to preserve efficacy against IL-12/23 and interferon-driven disease while avoiding some of the broader immunosuppressive and hematologic effects associated with less selective JAK inhibition.

By indication

Related mechanisms

TYK2 drugs compared

13 drugs, stage by indication
13 drugs acting on TYK2: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
deucravacitinibSotyktuBristol-Myers Squibbsmall moleculeApprovedApproved in Psoriasis; Approved in Psoriatic Arthritis; Phase 3 in Sjögren's Disease; Phase 3 in Systemic Lupus Erythematosus
EnvudeucitinibAlumis, Kaken Pharmaceuticalsmall moleculePhase 3Phase 3 in Psoriasis; Phase 2 in Systemic Lupus Erythematosus
FadeucravacitinibBeijing InnoCare Pharma Tech Co.small moleculePhase 3Phase 3 in Psoriasis
HS-10374Hansoh Pharmaceutical Groupsmall moleculePhase 3Phase 3 in Psoriasis; Phase 2 in Psoriatic Arthritis
Nomelcitinib (D-2570)InventisBioSmall molecule (oral TYK2 JH2 pseudokinase-domain inhibitor)Phase 3Phase 3 in Psoriasis; Phase 2 in Systemic Lupus Erythematosus; Phase 2 in Ulcerative Colitis; Phase 2 in Vitiligo
TQH3906Sino BiopharmaceuticalSmall molecule (oral TYK2 inhibitor)Phase 3Phase 3 in Psoriasis; Phase 2 in Psoriatic Arthritis; Phase 2 in Systemic Lupus Erythematosus; Phase 1 in Crohn's Disease; Phase 1 in Ulcerative Colitis
WD-890Ningbo/Zhejiang Wenda Pharma Technology Co.small moleculePhase 3Phase 3 in Psoriasis
zasocitinibTakeda Pharmaceutical Companysmall moleculePhase 3Phase 3 in Psoriasis; Phase 3 in Psoriatic Arthritis; Phase 2 in Hidradenitis Suppurativa; Phase 2 in Vitiligo
CMS-D001China Medical System, Dermavon Holdingssmall moleculePhase 2/3Phase 2/3 in Psoriasis; Phase 2 in Atopic Dermatitis
AC-201Accro Bioscience Limited, Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.small moleculePhase 2Phase 2 in Psoriasis
LomedeucitinibBeeline Medicines, Bristol-Myers Squibbsmall moleculePhase 2Phase 2 in Psoriasis
CS32582Chipscreen Biosciencessmall moleculePhase 1/2Phase 1/2 in Psoriasis
A-005Alumissmall moleculePhase 1Not recorded

← all mechanisms